An Exploratory Study on the Treatment of Chronic Obstructive Pulmonary Disease With Autologous Bronchial Basal Cell Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2021-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease(COPD)is characterized by recurrent cough, expectoration and asthma, and eventually develop chronic pulmonary heart disease ,chronic respiratory failure and even death. The current clinical treatments for these patients are symptomatic treatment cannot solve the problem of the damaged lung structure fundamentally. Recent studies show that bronchial basement the layer of cells is a kind of cells in the bronchial epithelial basal layer position, the specific expression of Krt5 antigen with the regeneration and repair of lung function , these cells have the activity similar to adult tissue stem cells. Its division and migration are more active and can continue to produce new cells to complement the death of other types of epithelial cells with functional plasticity which can be used to direct repair the bronchial and alveolar structures. It has been proved that bronchial basal cell transplantation can repair the damaged lungs of experimental animals . The bronchial basal cells from autologous tissue, so there is no immune rejection problem. Also because the bronchial basal cells derived from adult tissues which is a part of the body, so there is no risk of a tumor (in animal experiments, In animal experiments, bronchial basal cells transtracheal input 100 times in human dose still no tumor formation). In the early stage, patients with COPD (2 cases), bronchiectasis (2 cases) and interstitial lung disease (1 case) received the treatment, and the overall effect was good. Diseases were alleviated and recovered to some different extend.The study was to brush bronchial basal cells through fiberbronchoscopy in COPD patients and cultured in vitro, and then through the bronchoscope transfusion to the lesion site. To preliminary evaluate the efficacy and safety of autologous bronchial basal cells in the treatment of chronic obstructive pulmonary disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

NCT03092648

Chronic Obstructive Pulmonary Disease

UNKNOWN PHASE1/PHASE2

Autologous Bronchial Basal Cell Transplantation for Treatment of COPD

NCT03188627

Chronic Obstructive Pulmonary Disease

COMPLETED PHASE1/PHASE2

Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells

NCT03156673

Chronic Obstructive Pulmonary Disease

UNKNOWN EARLY_PHASE1

COPD Treatment by Transplantation of Autologous Bronchial Basal Cells

NCT05594303

Chronic Obstructive Pulmonary Disease (COPD)

COMPLETED PHASE1/PHASE2

Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF

NCT03153800

Chronic Respiratory Disease

UNKNOWN EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Between November 2016 and November 2019, the investigators initially recruited 20 with stable COPD patients. Primary evaluations including medical history, physical examination, anthropometric data, blood routine, blood biochemistry, blood coagulation, electrocardiogram,high resolution chest CT, arterial blood gas, pulmonary function test,6-min walking test(6MWT),modified medical research council(MMRC),St George's respiratory questionnaire(SGRQ). After initial evaluation, the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus to by mean of fiberbronchoscopy, then purified and selectively amplified bronchial basal cells to reserve .The basal layer cell culture system for our partners (Regend Therapeutics) patented technology using culture medium containing special combination of growth factors and composite materials to simulated composite basal layer environment and can selectively amplified bronchial basal cells, while other types of mature epithelial cells and fibroblasts could not grow naturally. After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site . Estimate the change of respiratory function(symptoms, signs, chest CT, pulmonary function, the 6 minute walk test, MMRC, SGRQ etc) and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively, to evaluate the safety and efficiency of autologous bronchial basal cells for treatment of COPD .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cell Transplantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COPD group(self control)

Prior treatment:20 stable COPD patients were enrolled,estimated the respiratory function and serum index Intervention:autologous bronchial basal cell transplantation After treatment:Estimate the change of respiratory function and serum index in third days , first months, third months, sixth months and first years of the follow-up after treatment respectively

Group Type OTHER

autologous bronchial basal cell transplantation

Intervention Type OTHER

the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

autologous bronchial basal cell transplantation

the investigators obtained extraction bronchial basal cells micro tissue from 3\~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. aged between 18 to 70 years
2. according to the guideline criteria, the diagnosis of COPD:

①There is a chronic cough, sputum or gas breathing symptoms such as promoting

②Pulmonary function tests showed airflow limitation(FEV1\<80% predicted value，FEV1/FVC\<0.7)
3. CT imaging and hematological examination excluded other lung diseases.
4. stable disease for more than 2 weeks
5. patients who were able to tolerate fiberoptic bronchoscopy
6. to sign the informed consent form

Exclusion Criteria

1. women who are pregnant, nursing or not taking effective contraception
2. syphilis, HIV antibody positive person
3. there is a history of alcohol or illicit drug abuse
4. patients who had received any other clinical trial within the first 3 months
5. poor compliance, it is difficult to complete the study
6. researchers believe there may be any increase in the risk of the subject or any interference with the clinical trial

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No